Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA's pentavalent pediatric vaccine pre qualified by World Health Organization


Monday, 5 May 2014 01:15am EDT 

Sanofi SA:Says that its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India, has received prequalification status from the World Health Organization.This status is based on a review of a comprehensive set of data related to the process and the product characteristics, as well as on a positive recommendation of WHO's auditors following a site inspection of Shantha's manufacturing facilities.It qualifies Shan5 vaccine for purchase by United Nations agencies, mainly UNICEF.Shan5 prequalification will give more children around the world access to the latest fully-liquid, 5-in-1 vaccine.And help secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries. 

Company Quote

80.43
-0.82 -1.01%
20 Oct 2014